We used Taiwan’s National Health Insurance Research Database to evaluate the effects of DPP4 inhibitors in combination with metformin compared to other oral antidiabetics (OADs) plus metformin on the risk of PD. This evidence concerns the gene DPP4 and Parkinson disease.